Insight Molecular Diagnostics Inc. (IMDX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts IMDX Hot Sheet
Join SI Premium – FREE
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) reported Q2 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $470.85 thousand.
For earnings history and earnings-related data on Insight Molecular Diagnostics Inc. (IMDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
- AI-powered cyber threats light a fire under cybersecurity stocks
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
